{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T18:12:24Z","timestamp":1792087944681,"version":"4.4.0"},"reference-count":58,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"},{"start":{"date-parts":[[2022,5,20]],"date-time":"2022-05-20T00:00:00Z","timestamp":1653004800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"name":"Beijing Hospitals Authority","award":["QMS20211101"],"award-info":[{"award-number":["QMS20211101"]}]},{"name":"Bejing Municipal Natural Science Foundation","award":["7214217"],"award-info":[{"award-number":["7214217"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81972562"],"award-info":[{"award-number":["81972562"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81972562"],"award-info":[{"award-number":["81972562"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Programmed cell death receptor-1 (PD-1) monotherapy is a standard treatment for advanced cutaneous melanoma, but its efficacy and toxicity are defined in white populations and remain poorly characterized in other ethnic groups, such as East Asian, Hispanic and African.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>To determine the efficacy and toxicity of PD-1 monotherapy in different ethnic groups.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Clinical data for patients with unresectable or advanced melanoma treated with anti-PD-1 monotherapy between 2009 and 2019 were collected retrospectively from five independent institutions in the USA, Australia and China. Tumour response, survival and immune-related adverse events (irAEs) were compared by ethnicity (white vs. East Asian\/Hispanic\/African) across different melanoma subtypes: nonacral cutaneous (NAC)\/unknown primary (UP) and acral\/mucosal\/uveal.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>In total, 1135 patients were included. White patients had significantly higher objective response rate (ORR) [54%, 95% confidence interval (CI) 50\u201357% vs. 20%, 95% CI 13\u201328%; adjusted P &amp;lt; 0\u00b7001] and longer progression-free survival (14\u00b72 months, 95% CI 10\u00b77\u201320\u00b73 vs. 5\u00b74 months, 95% CI 4\u00b75\u20137\u00b70; adjusted P &amp;lt; 0\u00b7001) than East Asian, Hispanic and African patients in the NAC and UP subtypes. White ethnicity remained independently associated with a higher ORR (odds ratio 4\u00b710, 95% CI 2\u00b748\u20136\u00b781; adjusted P &amp;lt; 0\u00b7001) and longer PFS (hazard ratio 0\u00b758, 95% CI 0\u00b746\u20130\u00b774; adjusted P &amp;lt; 0\u00b7001) in multivariate analyses after adjustment for age, sex, primary anatomical location, metastasis stage, baseline lactate dehydrogenase level, mutational status and prior systemic treatment. White and East Asian\/Hispanic\/African patients shared similar ORR and progression-free survival in acral\/mucosal\/uveal melanomas. Similar melanoma-subtype-specific ethnic discrepancies were observed in complete response rate and overall survival. White patients had higher rates of gastrointestinal irAEs but lower rates of endocrine, liver and other rare types of irAEs. These differences in irAEs by ethnicity were not attributable to varying melanoma subtypes.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Ethnic discrepancy in clinical benefit is specific to melanoma subtype, and East Asian, Hispanic and African patients with NAC and UP melanomas have poorer clinical benefits than previously recognized. The ethnic discrepancy in toxicity observed across different melanoma subtypes warrants an ethnicity-based irAE surveillance strategy. More research is needed to elucidate the molecular and immunological determinants of these differences.<\/jats:p>\n                  <jats:p>What is already known about this topic? There is a great difference in response to immunotherapy between different subtypes of melanoma (cutaneous, mucosal, acral and uveal) in patients with advanced disease.<\/jats:p>\n                  <jats:p>What does this study add? Our data show for the first time that there are differences between different ethnic groups in terms of both response and toxicity to immunotherapy beyond the well-appreciated discrepancies due to melanoma subtype.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1111\/bjd.21241","type":"journal-article","created":{"date-parts":[[2022,3,16]],"date-time":"2022-03-16T09:15:05Z","timestamp":1647422105000},"page":"401-410","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":60,"title":["Benefit and toxicity of programmed death-1 blockade vary by ethnicity in patients with advanced melanoma: an international multicentre observational study"],"prefix":"10.1093","volume":"187","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5203-4080","authenticated-orcid":false,"given":"Xue","family":"Bai","sequence":"first","affiliation":[{"name":"Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education, Beijing), Department of Melanoma and Sarcoma Peking University Cancer Hospital and Institute Beijing China"},{"name":"Massachusetts General Hospital Cancer Center Harvard Medical School Boston MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander N.","family":"Shoushtari","sequence":"additional","affiliation":[{"name":"Memorial Sloan Kettering Cancer Center Weill Cornell Medical College New York NY USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allison","family":"Betof Warner","sequence":"additional","affiliation":[{"name":"Memorial Sloan Kettering Cancer Center Weill Cornell Medical College New York NY USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Si","sequence":"additional","affiliation":[{"name":"Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education, Beijing), Department of Melanoma and Sarcoma Peking University Cancer Hospital and Institute Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bixia","family":"Tang","sequence":"additional","affiliation":[{"name":"Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education, Beijing), Department of Melanoma and Sarcoma Peking University Cancer Hospital and Institute Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuanliang","family":"Cui","sequence":"additional","affiliation":[{"name":"Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education, Beijing), Department of Melanoma and Sarcoma Peking University Cancer Hospital and Institute Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoling","family":"Yang","sequence":"additional","affiliation":[{"name":"Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education, Beijing), Department of Melanoma and Sarcoma Peking University Cancer Hospital and Institute Beijing China"},{"name":"Department of Medical Oncology Shanxi Bethune Hospital Shanxi China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0612-8465","authenticated-orcid":false,"given":"Xiaoting","family":"Wei","sequence":"additional","affiliation":[{"name":"Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education, Beijing), Department of Melanoma and Sarcoma Peking University Cancer Hospital and Institute Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry T.","family":"Quach","sequence":"additional","affiliation":[{"name":"Department of Medicine Vanderbilt University Medical Center Nashville TN USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher G.","family":"Cann","sequence":"additional","affiliation":[{"name":"Department of Medicine Vanderbilt University Medical Center Nashville TN USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael Z.","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Medicine Vanderbilt University Medical Center Nashville TN USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lalit","family":"Pallan","sequence":"additional","affiliation":[{"name":"Melanoma Institute Australia The University of Sydney, Royal North Shore and Mater Hospitals Sydney Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catriona","family":"Harvey","sequence":"additional","affiliation":[{"name":"Melanoma Institute Australia The University of Sydney, Royal North Shore and Mater Hospitals Sydney Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle S.","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Surgery Massachusetts General Hospital, Harvard Medical School Boston MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gyulnara","family":"Kasumova","sequence":"additional","affiliation":[{"name":"Department of Surgery Massachusetts General Hospital, Harvard Medical School Boston MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatyana","family":"Sharova","sequence":"additional","affiliation":[{"name":"Department of Surgery Massachusetts General Hospital, Harvard Medical School Boston MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justine V.","family":"Cohen","sequence":"additional","affiliation":[{"name":"Massachusetts General Hospital Cancer Center Harvard Medical School Boston MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald P.","family":"Lawrence","sequence":"additional","affiliation":[{"name":"Massachusetts General Hospital Cancer Center Harvard Medical School Boston MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Freedman","sequence":"additional","affiliation":[{"name":"Massachusetts General Hospital Cancer Center Harvard Medical School Boston MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riley M.","family":"Fadden","sequence":"additional","affiliation":[{"name":"Massachusetts General Hospital Cancer Center Harvard Medical School Boston MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krista M.","family":"Rubin","sequence":"additional","affiliation":[{"name":"Massachusetts General Hospital Cancer Center Harvard Medical School Boston MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennie T.","family":"Frederick","sequence":"additional","affiliation":[{"name":"Department of Surgery Massachusetts General Hospital, Harvard Medical School Boston MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3402-0478","authenticated-orcid":false,"given":"Keith T.","family":"Flaherty","sequence":"additional","affiliation":[{"name":"Massachusetts General Hospital Cancer Center Harvard Medical School Boston MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgina V.","family":"Long","sequence":"additional","affiliation":[{"name":"Melanoma Institute Australia The University of Sydney, Royal North Shore and Mater Hospitals Sydney Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander M.","family":"Menzies","sequence":"additional","affiliation":[{"name":"Melanoma Institute Australia The University of Sydney, Royal North Shore and Mater Hospitals Sydney Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan J.","family":"Sullivan","sequence":"additional","affiliation":[{"name":"Massachusetts General Hospital Cancer Center Harvard Medical School Boston MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Genevieve M.","family":"Boland","sequence":"additional","affiliation":[{"name":"Department of Surgery Massachusetts General Hospital, Harvard Medical School Boston MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas B.","family":"Johnson","sequence":"additional","affiliation":[{"name":"Department of Medicine Vanderbilt University Medical Center Nashville TN USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Guo","sequence":"additional","affiliation":[{"name":"Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education, Beijing), Department of Melanoma and Sarcoma Peking University Cancer Hospital and Institute Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,9,1]]},"reference":[{"key":"2023010808101626500_bjd21241-bib-0001","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","article-title":"Pembrolizumab versus ipilimumab in advanced melanoma","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"key":"2023010808101626500_bjd21241-bib-0002","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1056\/NEJMoa1412082","article-title":"Nivolumab in previously untreated melanoma without BRAF mutation","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"key":"2023010808101626500_bjd21241-bib-0003","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1093\/annonc\/mdt411","article-title":"Metastatic melanoma of unknown primary resembles the genotype of cutaneous melanomas","volume":"25","author":"Egberts","year":"2014","journal-title":"Ann Oncol"},{"key":"2023010808101626500_bjd21241-bib-0004","doi-asserted-by":"crossref","first-page":"4317","DOI":"10.1245\/s10434-014-3799-y","article-title":"Molecular characterization and patient outcome of melanoma nodal metastases and an unknown primary site","volume":"21","author":"Gos","year":"2014","journal-title":"Ann Surg Oncol"},{"key":"2023010808101626500_bjd21241-bib-0005","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1111\/pcmr.12153","article-title":"Melanomas of unknown primary have a mutation profile consistent with cutaneous sun-exposed melanoma","volume":"26","author":"Dutton-Regester","year":"2013","journal-title":"Pigment Cell Melanoma Res"},{"key":"2023010808101626500_bjd21241-bib-0006","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/j.jaad.2016.06.006","article-title":"Racial disparities in melanoma survival","volume":"75","author":"Dawes","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"2023010808101626500_bjd21241-bib-0007","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/j.suc.2014.07.008","article-title":"Melanoma in non-Caucasian populations","volume":"94","author":"Stubblefield","year":"2014","journal-title":"Surg Clin North Am"},{"key":"2023010808101626500_bjd21241-bib-0008","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1038\/nrc.2017.43","article-title":"Melanoma: a global perspective","volume":"17","author":"Ossio","year":"2017","journal-title":"Nat Rev Cancer"},{"key":"2023010808101626500_bjd21241-bib-0009","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/1471-2407-11-85","article-title":"Clinical presentation, histology, and prognoses of malignant melanoma in ethnic Chinese: a study of 522 consecutive cases","volume":"11","author":"Chi","year":"2011","journal-title":"BMC Cancer"},{"key":"2023010808101626500_bjd21241-bib-0010","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/nature22071","article-title":"Whole-genome landscapes of major melanoma subtypes","volume":"545","author":"Hayward","year":"2017","journal-title":"Nature"},{"key":"2023010808101626500_bjd21241-bib-0011","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1111\/pcmr.12279","article-title":"The mutational burden of acral melanoma revealed by whole-genome sequencing and comparative analysis","volume":"27","author":"Furney","year":"2014","journal-title":"Pigment Cell Melanoma Res"},{"key":"2023010808101626500_bjd21241-bib-0012","doi-asserted-by":"crossref","first-page":"3163","DOI":"10.1038\/s41467-019-11107-x","article-title":"Whole-genome landscape of mucosal melanoma reveals diverse drivers and therapeutic targets","volume":"10","author":"Newell","year":"2019","journal-title":"Nat Commun"},{"key":"2023010808101626500_bjd21241-bib-0013","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1016\/j.ajhg.2016.09.008","article-title":"Comprehensive genetic landscape of uveal melanoma by whole-genome sequencing","volume":"99","author":"Royer-Bertrand","year":"2016","journal-title":"Am J Hum Genet"},{"key":"2023010808101626500_bjd21241-bib-0014","doi-asserted-by":"crossref","first-page":"5259","DOI":"10.1038\/s41467-020-18988-3","article-title":"Whole-genome sequencing of acral melanoma reveals genomic complexity and diversity","volume":"11","author":"Newell","year":"2020","journal-title":"Nat Commun"},{"key":"2023010808101626500_bjd21241-bib-0015","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.immuni.2013.07.012","article-title":"Oncology meets immunology: the cancer\u2013immunity cycle","volume":"39","author":"Chen","year":"2013","journal-title":"Immunity"},{"key":"2023010808101626500_bjd21241-bib-0016","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1007\/s12094-017-1685-3","article-title":"Tumor infiltrating lymphocytes in acral lentiginous melanoma: a study of a large cohort of cases from Latin America","volume":"19","author":"Castaneda","year":"2017","journal-title":"Clin Transl Oncol"},{"key":"2023010808101626500_bjd21241-bib-0017","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1038\/labinvest.2017.64","article-title":"Melanoma subtypes demonstrate distinct PD-L1 expression profiles","volume":"97","author":"Kaunitz","year":"2017","journal-title":"Lab Invest"},{"key":"2023010808101626500_bjd21241-bib-0018","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.semcancer.2019.10.017","article-title":"Translational pathology, genomics and the development of systemic therapies for acral melanoma","volume":"61","author":"Chen","year":"2020","journal-title":"Semin Cancer Biol"},{"key":"2023010808101626500_bjd21241-bib-0019","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.pathol.2018.09.060","article-title":"Primary anorectal melanoma: clinical, immunohistology and DNA analysis of 43 cases","volume":"51","author":"Dodds","year":"2019","journal-title":"Pathology"},{"key":"2023010808101626500_bjd21241-bib-0020","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1158\/1078-0432.CCR-05-1544","article-title":"Tumor antigen expression in melanoma varies according to antigen and stage","volume":"12","author":"Barrow","year":"2006","journal-title":"Clin Cancer Res"},{"key":"2023010808101626500_bjd21241-bib-0021","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1097\/PAS.0000000000001134","article-title":"PRAME expression in melanocytic tumors","volume":"42","author":"Lezcano","year":"2018","journal-title":"Am J Surg Pathol"},{"key":"2023010808101626500_bjd21241-bib-0022","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1038\/s41379-019-0335-4","article-title":"Analyses of molecular and histopathologic features and expression of PRAME by immunohistochemistry in mucosal melanomas","volume":"32","author":"Toyama","year":"2019","journal-title":"Mod Pathol"},{"key":"2023010808101626500_bjd21241-bib-0023","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1001\/jamaophthalmol.2017.0729","article-title":"PRAME as a potential target for immunotherapy in metastatic uveal melanoma","volume":"135","author":"Gezgin","year":"2017","journal-title":"JAMA Ophthalmol"},{"key":"2023010808101626500_bjd21241-bib-0024","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1136\/bjophthalmol-2011-300432","article-title":"Expression of cancer-testis antigens (MAGE-A1, MAGE-A3\/6, MAGE-A4, MAGE-C1 and NY-ESO-1) in primary human uveal and conjunctival melanoma","volume":"96","author":"Errington","year":"2012","journal-title":"Br J Ophthalmol"},{"key":"2023010808101626500_bjd21241-bib-0025","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1158\/1078-0432.CCR-15-2294","article-title":"Identification of an immunogenic subset of metastatic uveal melanoma","volume":"22","author":"Rothermel","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"aar3342","key":"2023010808101626500_bjd21241-bib-0026","article-title":"MHC proteins confer differential sensitivity to CTLA-4 and PD-1 blockade in untreated metastatic melanoma","volume":"10","author":"Rodig","year":"2018","journal-title":"Sci Transl Med"},{"key":"2023010808101626500_bjd21241-bib-0027","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1002\/(SICI)1097-0215(19970410)71:2<142::AID-IJC3>3.0.CO;2-0","article-title":"Immunoselection in vivo: independent loss of MHC class I and melanocyte differentiation antigen expression in metastatic melanoma","volume":"71","author":"Jager","year":"1997","journal-title":"Int J Cancer"},{"key":"2023010808101626500_bjd21241-bib-0028","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1111\/j.1399-0039.2005.00381.x","article-title":"Selective monomorphic and polymorphic HLA class I antigenic determinant loss in surgically removed melanoma lesions","volume":"65","author":"Kageshita","year":"2005","journal-title":"Tissue Antigens"},{"key":"2023010808101626500_bjd21241-bib-0029","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1146\/annurev-pathol-012513-104658","article-title":"The molecular pathology of melanoma: an integrated taxonomy of melanocytic neoplasia","volume":"9","author":"Bastian","year":"2014","journal-title":"Annu Rev Pathol"},{"key":"2023010808101626500_bjd21241-bib-0030","doi-asserted-by":"crossref","first-page":"3344","DOI":"10.1002\/cncr.30258","article-title":"Clinical outcomes in metastatic uveal melanoma treated with PD-1 and PD-L1 antibodies","volume":"122","author":"Algazi","year":"2016","journal-title":"Cancer"},{"key":"2023010808101626500_bjd21241-bib-0031","doi-asserted-by":"crossref","first-page":"1908065","DOI":"10.1155\/2018\/1908065","article-title":"Efficacy of immunotherapy in patients with metastatic mucosal or uveal melanoma","volume":"2018","author":"Mignard","year":"2018","journal-title":"J Oncol"},{"key":"2023010808101626500_bjd21241-bib-0032","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1200\/JCO.2016.67.9258","article-title":"Efficacy and safety of nivolumab alone or in combination with ipilimumab in patients with mucosal melanoma: a pooled analysis","volume":"35","author":"D\u2019Angelo","year":"2017","journal-title":"J Clin Oncol"},{"key":"2023010808101626500_bjd21241-bib-0033","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1016\/j.annonc.2020.05.031","article-title":"Anti-PD1 checkpoint inhibitor therapy in acral melanoma: a multicenter study of 193 Japanese patients","volume":"31","author":"Nakamura","year":"2020","journal-title":"Ann Oncol"},{"issue":"eaar3593","key":"2023010808101626500_bjd21241-bib-0034","article-title":"Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy","volume":"362","author":"Cristescu","year":"2018","journal-title":"Science"},{"key":"2023010808101626500_bjd21241-bib-0035","doi-asserted-by":"crossref","first-page":"4250","DOI":"10.1158\/1078-0432.CCR-19-3922","article-title":"Safety, efficacy, and biomarker analysis of toripalimab in previously treated advanced melanoma: results of the POLARIS-01 multicenter phase II trial","volume":"26","author":"Tang","year":"2020","journal-title":"Clin Cancer Res"},{"key":"2023010808101626500_bjd21241-bib-0036","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1007\/s00262-019-02318-8","article-title":"Autoimmune genetic risk variants as germline biomarkers of response to melanoma immune-checkpoint inhibition","volume":"68","author":"Chat","year":"2019","journal-title":"Cancer Immunol Immunother"},{"key":"2023010808101626500_bjd21241-bib-0037","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/j.immuni.2018.03.023","article-title":"The immune landscape of cancer","volume":"48","author":"Thorsson","year":"2018","journal-title":"Immunity"},{"key":"2023010808101626500_bjd21241-bib-0038","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s41065-018-0057-5","article-title":"Genetic structure, divergence and admixture of Han Chinese, Japanese and Korean populations","volume":"155","author":"Wang","year":"2018","journal-title":"Hereditas"},{"key":"2023010808101626500_bjd21241-bib-0039","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1093\/jnci\/djz005","article-title":"Targeted genomic profiling of acral melanoma","volume":"111","author":"Yeh","year":"2019","journal-title":"J Natl Cancer Inst"},{"key":"2023010808101626500_bjd21241-bib-0040","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1186\/s40425-019-0602-4","article-title":"Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshop","volume":"7","author":"Bedognetti","year":"2019","journal-title":"J Immunother Cancer"},{"key":"2023010808101626500_bjd21241-bib-0041","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1126\/science.aao4572","article-title":"Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy","volume":"359","author":"Chowell","year":"2018","journal-title":"Science"},{"key":"2023010808101626500_bjd21241-bib-0042","doi-asserted-by":"crossref","first-page":"472","DOI":"10.3322\/caac.21409","article-title":"Melanoma staging: evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual","volume":"67","author":"Gershenwald","year":"2017","journal-title":"CA Cancer J Clin"},{"key":"2023010808101626500_bjd21241-bib-0043","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1002\/(SICI)1097-0142(19981015)83:8<1664::AID-CNCR23>3.0.CO;2-G","article-title":"The National Cancer Data Base report on cutaneous and noncutaneous melanoma: a summary of 84,836 cases from the past decade. The American College of Surgeons Commission on Cancer and the American Cancer Society","volume":"83","author":"Chang","year":"1998","journal-title":"Cancer"},{"key":"2023010808101626500_bjd21241-bib-0044","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.ejca.2017.05.038","article-title":"Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1\/cytotoxic T-lymphocyte antigen-4 inhibition","volume":"82","author":"Heppt","year":"2017","journal-title":"Eur J Cancer"},{"key":"2023010808101626500_bjd21241-bib-0045","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1038\/bjc.2017.70","article-title":"Evaluation of clinicopathological factors in PD-1 response: derivation and validation of a prediction scale for response to PD-1 monotherapy","volume":"116","author":"Nosrati","year":"2017","journal-title":"Br J Cancer"},{"key":"2023010808101626500_bjd21241-bib-0046","doi-asserted-by":"crossref","first-page":"5347","DOI":"10.1158\/1078-0432.CCR-18-1116","article-title":"Age correlates with response to anti-PD1, reflecting age-related differences in intratumoral effector and regulatory T-cell populations","volume":"24","author":"Kugel","year":"2018","journal-title":"Clin Cancer Res"},{"key":"2023010808101626500_bjd21241-bib-0047","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/S1470-2045(18)30261-4","article-title":"Cancer immunotherapy efficacy and patients\u2019 sex: a systematic review and meta-analysis","volume":"19","author":"Conforti","year":"2018","journal-title":"Lancet Oncol"},{"key":"2023010808101626500_bjd21241-bib-0048","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.ejca.2019.05.015","article-title":"Efficacy of PD-1-based immunotherapy after radiologic progression on targeted therapy in stage IV melanoma","volume":"116","author":"Kreft","year":"2019","journal-title":"Eur J Cancer"},{"key":"2023010808101626500_bjd21241-bib-0049","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/S0140-6736(14)60958-2","article-title":"Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial","volume":"384","author":"Robert","year":"2014","journal-title":"Lancet"},{"key":"2023010808101626500_bjd21241-bib-0050","doi-asserted-by":"crossref","first-page":"2226","DOI":"10.1158\/1078-0432.CCR-20-4189","article-title":"Therapeutic implications of detecting MAPK-activating alterations in cutaneous and unknown primary melanomas","volume":"27","author":"Shoushtari","year":"2021","journal-title":"Clin Cancer Res"},{"key":"2023010808101626500_bjd21241-bib-0051","doi-asserted-by":"crossref","first-page":"e1226","DOI":"10.1002\/onco.13780","article-title":"Analysis of real-world data to investigate the impact of race and ethnicity on response to programmed cell death-1 and programmed cell death-ligand 1 inhibitors in advanced non-small cell lung cancers","volume":"26","author":"Ayers","year":"2021","journal-title":"Oncologist"},{"key":"2023010808101626500_bjd21241-bib-0052","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1038\/s41591-019-0639-4","article-title":"Evolutionary divergence of HLA class I genotype impacts efficacy of cancer immunotherapy","volume":"25","author":"Chowell","year":"2019","journal-title":"Nat Med"},{"key":"2023010808101626500_bjd21241-bib-0053","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s12979-020-00195-9","article-title":"Genetic and environmental determinants of human TCR repertoire diversity","volume":"17","author":"Krishna","year":"2020","journal-title":"Immun Ageing"},{"key":"2023010808101626500_bjd21241-bib-0054","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1016\/j.cell.2015.05.044","article-title":"Genomic classification of cutaneous melanoma","volume":"161","author":"Cancer Genome Atlas Network","year":"2015","journal-title":"Cell"},{"key":"2023010808101626500_bjd21241-bib-0055","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1038\/s41586-020-1943-3","article-title":"The repertoire of mutational signatures in human cancer","volume":"578","author":"Alexandrov","year":"2020","journal-title":"Nature"},{"key":"2023010808101626500_bjd21241-bib-0056","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1038\/s41586-020-1969-6","article-title":"Pan-cancer analysis of whole genomes","volume":"578","author":"ICGC\/TCGA Pan-Cancer Analysis of Whole Genomes Consortium","year":"2020","journal-title":"Nature"},{"key":"2023010808101626500_bjd21241-bib-0057","doi-asserted-by":"crossref","first-page":"4128","DOI":"10.1038\/s41467-020-17981-0","article-title":"Strength of immune selection in tumors varies with sex and age","volume":"11","author":"Castro","year":"2020","journal-title":"Nat Commun"},{"key":"2023010808101626500_bjd21241-bib-0058","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/nrendo.2018.18","article-title":"Global epidemiology of hyperthyroidism and hypothyroidism","volume":"14","author":"Taylor","year":"2018","journal-title":"Nat Rev Endocrinol"}],"container-title":["British Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjd.21241","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/bjd.21241","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/187\/3\/401\/48528727\/bjd0401.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/187\/3\/401\/48528727\/bjd0401.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,14]],"date-time":"2023-02-14T14:10:14Z","timestamp":1676383814000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjd\/article\/187\/3\/401\/6966614"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,1]]},"references-count":58,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2022,9,1]]},"published-print":{"date-parts":[[2022,9,1]]}},"URL":"https:\/\/doi.org\/10.1111\/bjd.21241","relation":{},"ISSN":["1365-2133","0007-0963"],"issn-type":[{"value":"1365-2133","type":"electronic"},{"value":"0007-0963","type":"print"}],"subject":[],"published-other":{"date-parts":[[2022,9,1]]},"published":{"date-parts":[[2022,9,1]]},"assertion":[{"value":"2021-11-16","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-03-11","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-05-20","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}